



Attorney Docket No. 25352-0027

CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the US Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on August 28, 2002.

Derek P. Freyberg
Derek P. Freyberg, Reg. No. 29,250

8/28/02
Date

1614
#4
9/13/02
83
RECEIVED
PATENTS
TECH CENTER 1600/2900
SEP 04 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Edgardo Laborde, et al.

: Confirmation No: 9701

App. No.: 10/072,308 ✓

: Group Art No.: 1614

Filing Date: February 05, 2002 ✓

: Examiner: Not Known

For: HETEROCYCLIC INHIBITORS OF GLYCINE TRANSPORTER 2 ✓

Commissioner for Patents
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

Applicants direct the attention of the Office to the documents listed on the attached Form PTO-1449 substitute (2 sheets), which may be relevant to the examination of this application.


~~This application claims the benefit under 35 USC 119(e) of Application No. 60/267,894, filed February 9, 2001.~~

Documents 5, 17, 25 and 33 through 36 were cited in an International Search Report (copy enclosed) issuing on a PCT application corresponding to this application (PCT/US 02/03837); and their relevance is believed to be as explained therein.

The Examiner is requested to initial and return a copy of each of these forms with future communications relating to this application.

No representation is made by this Information Disclosure Statement that a search has been made; or that the information disclosed is, or is considered to be, material to patentability under 37 CFR 1.56(b).

Respectfully submitted,


A handwritten signature in black ink, appearing to read "Derek P. Freyberg", followed by a checkmark.

Derek P. Freyberg
Attorney for Applicant
Reg. No. 29,250

Heller Ehrman White & McAuliffe LLP
275 Middlefield Road
Menlo Park, CA 94025-3506
(650) 324-7014
August 28, 2002

375516 v01.SV (81R001!.DOC)
08/28/02 2:36 PM

4

 <p>37 CFR 1.56, 1.97, and 1.98)</p> <p>SHEET 1 OF 2</p>	ATTORNEY DOCKET 25352-0027	APPLICATION NO. 0972,808
	APPLICANT(S) Edgardo Laborde, et al.	
	FILING DATE February 5, 2002	GROUP

U.S. PATENT DOCUMENTS

† EX'R INITIAL	* REF. #	PATENT NUMBER	DATE (MO/YR)	NAME	CLASS/ SUBCLASS	FILING DATE (If appropriate)
	1	4,097,669	06/1978	Reisdorff et al.	542/413	
	2	4,325,959	04/1982	Matthews	31/425	
	3	5,587,293	12/1996	Kauvar et al.	435/7.21	
	4	5,668,159	09/1997	Jin	514/363	
	5	5,670,526	09/1997	Dodd et al.	514/340	
	6	5,756,348	03/1998	Smith et al.	435/325	
	7	5,968,823	10/1999	Borden et al.	435/349	
	8	6,008,015	12/1999	Albert et al.	435/69.1	
	9	6,127,131	10/2000	Smith et al.	435/7.1	

FOREIGN PATENT DOCUMENTS

† EX'R INITIAL	* REF. #	COUNTRY	PATENT NUMBER	DATE (MO/YR)	APPLICANT	TRANSLATION?
	10	DE	25 33 605	06/1978	Bayer AG	Abstract only, equiv. to Ref. #1
	11	DE	30 31 191	03/1981	Ciba Geigy AG	Abstract
	12	DE	37 17 865	12/1988	Schering AG	Abstract
	13	EP	0 214 732 A2	03/1987	Yamanouchi Pharmaceutical Co., Ltd.	
	14	EP	0 276 793 A2	01/1988	Merrell Dow Pharmaceuticals Inc.	
	15	EP	0 409 332 A2	01/1991	Merck & Co., Inc.	
	16	EP	0 554 107 A1	08/1993	Ortho Pharmaceutical Corporation	
	17	GB	2 263 635 A	08/1993	Merck & Co., Inc.	
	18	JP	2-129173	05/1990	Ishihara Sangyo Co., Ltd.	Abstract
	19	JP	5-202038	08/1993	Sumitomo Chemical Industries Co., Ltd.	Abstract
	20	JP	7-005646	01/1995	Konica Corporation	Abstract
	21	JP	9-114055	05/1997	Konica Corporation	Abstract
	22	JP	10-036357	02/1998	Mitsubishi Kagaku Co., Ltd.; Rhône Poulenc Agrochimie	Abstract
	23	JP	11-043485	06/1989	Chisso Corporation	Abstract

EXAMINER'S SIGNATURE

DATE CONSIDERED

† EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered. *Include copy of this form in next communication to applicant.*

* If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. 1.98(d).

No Ref's Recvd.

INFORMATION DISCLOSURE STATEMENT

37 CFR 1.56, 1.97, and 1.98)

SHEET 2 OF 2

25352-0027

APPLICANT(S)

Edgardo Laborde et al.

FILING DATE

February 5, 2002

GROUP

FOREIGN PATENT DOCUMENTS

† EX'R INITIAL	REF. #	COUNTRY	PATENT NUMBER	DATE (MO/YR)	APPLICANT	TRANSLATION?
	24	WO	91/11909	08/1991	Merck & Co., Inc.	
	25	WO	95/13268	05/1995	Gyógyszerkutató Intézet Kft.	
	26	WO	97/45115	12/1997	Trophix Pharmaceuticals, Inc.	
	27	WO	97/45423	12/1997	Trophix Pharmaceuticals, Inc.	
	28	WO	98/30561	07/1998	EGIS Gyógyszergyár Rt.	
	29	WO	99/44596	09/1999	Janssen Pharmaceutica N.V.	
	30	WO	99/45011	09/1999	Janssen Pharmaceutica N.V.	
	31	WO	01/57024	08/2001	University College London	
	32	WO	01/87855	11/2001	Yamanouchi Pharmaceutical Co., Ltd.; Merck Patent GmbH	Abstract

OTHER DOCUMENTS

† EX'R INITIAL	* REF. #	CITATION (Author, Article Title, Journal/Book Title, Date, Pertinent Pages, etc.)
	33	Hazzaa et al., "Synthesis and biological evaluation of 3-quinolyl-5-mercapto-1,2,4-triazoles, <i>Sci Pharm</i> , 46(4), 298-306 (1978)
	34	Gulerman et al., "Evaluation of antimycobacterial and anticonvulsant activities of new 1-(4-fluorobenzoyl)-4-substituted-2,4-dihydro-3H-1,2,4-triazole-3-thione derivatives", <i>Il Farmaco</i> , 52(11), 691-695 (1997)
	35	<i>Chem Abs</i> , 128(3), 22862 (1998); Abstract of Habib et al., "Synthesis and antimicrobial testing of novel oxadiazolylbenzimidazole derivatives", <i>Pharmazie</i> , 52(10), 746-749 (1997)
	36	<i>Biosis Database</i> , Abstract No. PREV200100076408 (2000); Abstract of Lechner et al., "Novel glycine transporter 2 inhibitors are analgesic in a rat model of inflammatory pain", <i>Soc Neurosci Abs</i> , 26(1-2), Abstract 150.18 (2000)

EXAMINER'S SIGNATURE

DATE CONSIDERED

† EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered. Include copy of this form in next communication to applicant.

* If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. 1.98(d).